biobide

FEBRUARY 2, 2024

Pediatric cancers exhibit differences at the genetic level compared to the same form of adult disease, which may influence the selected treatment. Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies.

Disease 59

Disease Medical Schools Pharma Companies Clinical Trials 59

Drug Target Review

FEBRUARY 29, 2024

Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapy drug development. AskBio) I continue to work to bring innovative gene therapies to patients in need. In my current role at Asklepios BioPharmaceutical, Inc.

Therapies 111

Therapies Disease Clinical Trials Science 111

Broad Institute

FEBRUARY 7, 2024

It examined endothelial mechanisms unrelated to lipid metabolism (a known driver of CAD risk with effective therapies, like statins) in hopes of uncovering other mechanisms driving CAD risk for which therapies may yet be developed. “Now

Disease 105

Disease Hospitals Medical Schools Therapies 105

Broad Institute

JANUARY 25, 2024

“This could potentially help with disease prevention — if we know from someone’s retinal image that they are at high risk of developing glaucoma or cardiovascular disease in the future, we could refer them for follow-up screening or preventative treatment.”

Disease 124

Disease Research Science Medical Schools 124

Drug Target Review

JUNE 6, 2023

We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. In this IO arena, we continue to search for additional treatments that can further benefit patients. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Broad Institute

OCTOBER 23, 2024

They knew that discovering the genetic cause of her disorder would help them find other people like her, help get the condition formally recognized as a new disease, and help them better advocate for research into new treatments. It wasn’t until Emma that this possibility came on everyone’s radar,” said Carvill.

DNA 128

DNA RNA Disease Hospitals 128

The Pharma Data

SEPTEMBER 18, 2020

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi and Regeneron’s jointly-developed PD-1 inhibitor Libtayo (cemiplimab) in the treatment of locally advanced basal cell carcinoma (BCC) in patients for whom hedgehog inhibitor (HHI) therapy is not applicable.

Medical Schools 52

Medical Schools Trials Therapies Hospitals 52

Drug Target Review

FEBRUARY 26, 2024

Regarding therapy resistant melanomas, why is the alteration of the epigenetic landscape considered significant, and what has been lacking in terms of validated targetable epigenetic mechanisms? What is remarkable here is that we show that the addition of corin to BRAFi-resistant tumour cells resensitises them to BRAFi therapies.

Therapies 59

Therapies Molecular Biology Medical Schools Regulations 59

The Pharma Data

JANUARY 25, 2021

from Harvard Medical School in Boston, and colleagues developed evidence-based guidelines for the management of VWD and agreed on 12 recommendations. Connell, M.D., president and chief executive officer of the National Hemophilia Foundation, said in a statement. Guidelines: Diagnosis. Guidelines: Management. © 2021 HealthDay.

Disease 52

Disease Medical Schools Laboratories Therapies 52

Broad Institute

OCTOBER 4, 2023

The molecule’s dual mechanism of action — targeting both tumor and immune cells — is unique compared to other cancer immunotherapies including PD-1 drugs, and the researchers think it could explain why the molecule was so effective on its own in animal models and may not even need to be used in combination with other drugs such as anti-PD-1 therapy.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

JUNE 2, 2023

With only one currently approved treatment option, I see HS patients with a tremendous need for alternatives that reduce the disabling physical symptoms of HS, improve the emotional burden and help partially avoid invasive surgery, if treating early,” said Professor Christos C.

Medical Schools 52

Medical Schools Treatment Disease Therapies 52

The Pharma Data

JANUARY 17, 2021

Ophthalmologists are physicians who have completed four years of medical school and four years of residency training. Treatments they help administer include patching therapy, prisms and convergence exercises. Danielle Natale, an optometrist at the Krieger Eye Institute in Baltimore, said in an institute news release.

Medical Schools 52

Medical Schools Doctors Treatment Disease 52

The Pharma Data

NOVEMBER 10, 2020

from Harvard Medical School in Boston, and colleagues developed machine learning models to predict antibiotic susceptibility using electronic health record data and built a decision algorithm for recommending the narrowest possible antibiotic to which a specimen is susceptible for the treatment of uncomplicated UTI.

Medical Schools 52

Medical Schools Science Therapies Trials 52

The Pharma Data

NOVEMBER 22, 2020

The mice who received the treatment had double the life expectancy as their counterparts, with a 30% higher survival rate. Peer stated that his team plans to develop a treatment for all cancers and that their technique could be ready for humans within the next two years.

DNA 52

DNA Medical Schools Treatment Science 52

The Pharma Data

JUNE 2, 2022

The partnership with ASH will not only deliver better tools to track a baby’s diagnosis, but also support greater knowledge on treatment and care, including through publications on research findings, professional education and dissemination to policy makers and other audiences. Winter, MD, of the Robert H.

Disease 52

Disease Medical Schools Treatment Therapies 52

On Medicine

APRIL 6, 2023

I have a background in Biomedical Engineering prior to medical school and a particular interest in global health and healthcare in resource-limited settings. I continued working in this field and I did my PhD thesis on anthracycline-induced cardiotoxicity during and after treatment for childhood cancer.

Medical Schools 52

Medical Schools Hospitals Treatment International 52

The Pharma Data

MAY 17, 2021

. In a Viewpoint, Bishal Gyawali, MD, PhD, and colleagues at the Program on Regulation, Therapeutics and Law (PORTAL) research group at Harvard Medical School and Brigham & Women’s Hospital suggested improving FDA’s authority to modify drug package insert for situations such as drug repurposing and de-escalation of therapy.

Research 52

Research FDA Approval Drugs FDA 52

The Pharma Data

APRIL 22, 2023

This latest breakthrough discovery, published in the high impact scientific journal Nature Communications on 27 March 2023, has implications for the development of novel strategies for cancer treatment. “Using a treatment to alleviate stress on immune cells, we found that immune cells were able to kill cancer cells more effectively.

Medical Schools 40

Medical Schools Therapies Treatment Hospitals 40

Broad Institute

AUGUST 4, 2022

By Tracy Hampton August 4, 2022 Credit: National Institutes of Allergy and Infectious Diseases, National Institutes of Health Colorized scanning electron micrograph of a B cell lymphocyte from a human donor.

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52

The Pharma Data

JUNE 7, 2023

These longer-term results show the durable overall survival benefit of sacituzumab govitecan over traditional chemotherapy in pre-treated HR+/HER2- metastatic breast cancer,” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School. “At

Medical Schools 40

Medical Schools Therapies Treatment Clinical Development 40

The Pharma Data

JANUARY 26, 2021

Dr. Short brings to VarmX extensive clinical development expertise, with a particular focus on rare diseases and gene therapy for haematological disorders. During this time, he grew the medical, clinical, and regulatory groups, and established an in-house pharmacovigilance function.

Clinical Development 40

Clinical Development Medical Schools Therapies Pharmaceuticals 40

The Pharma Data

JANUARY 25, 2021

Checkpoint inhibitors, like the cancer vaccine, fall under the umbrella of “immunotherapy” — treatments that enlist the immune system to help destroy tumor cells. NeoVax is being studied as an additional therapy for other cancers, including later-stage ovarian and kidney cancers. SOURCES: Patrick A. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

Solomon of Brigham and Women’s Hospital and Harvard Medical School, Boston, found that current evidence in humans is insufficient to support or refute claims that ACE inhibitors or ARBs may be helpful or harmful to individuals with COVID-19. In a new report in this week’s New England Journal of Medicine , a team of U.K.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

KIF1A

MAY 31, 2024

From hosting a conference to scientific projects and collaborations to the dedicated efforts of our team, this review encapsulates the relentless pursuit to accelerate treatments and a cure for all KAND warriors. The Chung Lab spearheads a robust KAND program to better understand the disorder and discover treatments.

Treatment 52

Treatment Small Molecule International Research 52

NIH Director's Blog: Drug Discovery

DECEMBER 9, 2014

Tanzi, Massachusetts General Hospital/ Harvard Medical School Researchers want desperately to develop treatments to help the more than 5 million Americans with Alzheimer’s disease and the millions more at risk. Credit: Doo Yeon Kim and Rudolph E.

Drugs 52

Drugs Disease Hospitals Medical Schools 52

The Pharma Data

DECEMBER 28, 2020

Scopus is a biopharmaceutical company whose lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. Dr. Hofstein completed his postdoctoral training and research in the Department of Neurobiology at Harvard Medical School. Hofstein received his B.Sc.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Government Therapies 52

The Pharma Data

DECEMBER 15, 2020

In late 2020, the effort received $200,000 in seed funding from the Baker Department of Cardiometabolic Health at the University of Melbourne’s medical school. Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MARCH 13, 2021

Donanemab has the potential to become a very important treatment for Alzheimer’s disease. ” Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. percent), nausea (10.7 In the donanemab arm, 30.5

Disease 40

Disease Trials Treatment Medical Schools 40

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 116

Therapies Disease Engineering Medical Schools 116

Broad Institute

JUNE 1, 2023

Without prompt diagnosis and treatment, hypertensive disorders of pregnancy (HDPs) can lead to organ failure and potentially fatal complications. But scientists lack the tools to predict, prevent, and treat them. Buu Truong, a computational researcher and postdoctoral fellow in Natarajan’s lab, was a co-first author as well.

Doctors 133

Doctors Medical Schools Hospitals DNA 133

Broad Institute

DECEMBER 6, 2023

For many immune-mediated diseases, there's no cure or treatment. Some patients develop resistance to treatment and we cannot predict who they will be. I hope our approach helps scientists make sense of any immune process, vaccine, disease, or therapy response, so that one can infer which cytokines are contributing to it.

Immune Response 138

Immune Response RNA Disease Medical Schools 138

Drug Target Review

JANUARY 15, 2024

Monoclonal antibodies (mAbs) targeting tumour-specific antigens play an essential role in the treatment of many cancers. As new higher‑throughput methods of discovery and biologic drug development come online, we can expect TCR-based therapeutics to play an important role in the treatment of cancer and other diseases in the coming years.

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both of the new gene therapy studies were published online Dec. SATURDAY, Dec. 5 in the New England Journal of Medicine.

Therapies 52

Therapies Disease Medical Schools Virus 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. These findings can then be used to predict response to treatments as well as survival time. Their report appears in Nature.

Treatment 68

Treatment FDA Approval DNA Small Molecule 68

Drug Target Review

MAY 16, 2024

Symptom-based treatment is often accompanied by undesirable side effects. 1,2 The application of endogenous compounds is a highly pragmatic approach for the creation of disease-modifying therapies. Examples include insulin for the treatment of diabetes and human somatotropin to promote physical growth.

Disease 64

Disease Therapies Medical Schools Treatment 64

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. “Current MS therapies do not specifically target myeloid cells. who is a Core Faculty member at the Wyss Institute.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

Broad Institute

MAY 2, 2024

She aims to better understand how cancers evolve during treatment and throughout a patient’s lifetime. In undergrad, I thought about going to medical school, but I didn’t want to work in a hospital. When Martin started working at the Broad, she also joined the Riverside Boat Club in Cambridge, Massachusetts.

Science 124

Science Medical Schools Disease Hospitals 124